To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
AbirateroneAbiraterone is currently a drug under investigation for use in prostate cancer. It blocks the formation of testosterone by inhibiting CYP17A1 (CYP450c17), an enzyme also known as 17α-hydroxylase/17,20 lyase.[1] This enzyme is involved in the formation of DHEA and androstenedione, which may ultimately be metabolized into testosterone. Additional recommended knowledgeThe results of two Phase II trials indicate that abiraterone may reduce prostate specific antigen (PSA) levels, as well as shrink tumors.[2] A Phase III trial is planned for 2008. References
|
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Abiraterone". A list of authors is available in Wikipedia. |